FIGURE LEGENDS

1

15

16

17

groups.

2 **SupplementaryFigure 1.** The cumulative incidences (CIs) of GvHD after Haplo-HSCT. 3 The CIs of grades II-IV aGvHD, grades III-IV aGvHD, cGvHD and moderate to severe 4 cGvHD were shown in (A), (B), (C) and (D),respectively. The CIs of grades II-IV 5 aGvHD and grades III-IV aGvHD were significantly lower in the low dose ATG/PTCy 6 than that in the standard ATG dose group (P=0.042 and P=0.025, respectively). There 7 was no significant difference concerning the CIs of cGvHD (P=0.190) between the two 8 groups. The CI of moderate to severe cGvHD was significantly lower in the low dose 9 ATG/PTCy than that in the standard ATG dose group(P=0.029). 10 SupplementaryFigure 2. The cumulative incidences(CIs) of relapse and NRM (A), 11 the overall survival (OS) (B), and the leukemia free survival (LFS) (C). The CI of 12 relapse was significantly higher in the low dose ATG/PTCy than that in the standard 13 ATG dose group (P=0.042). The CI of NRM was significantly lower in the low dose 14 ATG/PTCy than that in the standard ATG dose group(P=0.038). There were no

significant differences concerning OS (P=0.255), and LFS(P=0.400)between the two